肝脏射频消融计算机模拟规划与实时仿真的临床评估(ClinicIMPPACT试验)
这项前瞻性多中心试验纳入45例患者共51个肝脏恶性病灶,评估综合仿真工具在CT引导射频消融前规划与预测消融区的准确性和临床可整合性。仿真与术后1个月分割的消融区体积显著相关(ρ=0.59,p<0.0001)且无显著偏倚,但平均表面偏差为3.4±1.7 mm,仿真使操作时间较历史对照组增加3.5±1.9 min。作者认为该工具有可接受的速度和准确性,需进一步随机对照试验评估其能否改善患者结局。
要点
- 仿真消融区与术后1个月CT分割消融区体积显著相关(ρ=0.59,p<0.0001),无显著偏倚(Wilcoxon Z=0.68,p=0.25)。
- 仿真与分割消融区的平均表面偏差(绝对平均误差)为3.4±1.7 mm,Dice相似系数0.62±0.14,敏感度0.70±0.21,阳性预测值0.66±0。
- 仿真工具使操作时间较历史对照组增加3.5±1.9 min,作者认为其速度和准确性可接受。
核心结论
- 经验证的仿真工具在预测肝脏射频消融区大小和形状方面显示出可接受的速度和准确性,需进一步随机对照试验评估该工具可能在多大程度上改善患者结局。
研究设计与样本
- 前瞻性多中心试验,纳入45例患者共51个不同来源的肝脏恶性病灶,术前多期CT(含肝脏灌注采集)生成肝脏3D模型,术中CT确定射频消融探针位置并半自动配准至3D模型,术后1个月增强CT分割热消融区与仿真消融区比较,操作时间与历史对照组比较。
关键影像表现/征象
- 仿真与分割消融区体积显著相关(ρ=0.59,p<0.0001),无显著偏倚(Wilcoxon Z=0.68,p=0.25)。
- 平均表面偏差(绝对平均误差)为3.4±1.7 mm,Dice相似系数0.62±0.14,敏感度0.70±0.21,阳性预测值0.66±0。
- 平均表面偏差与消融持续时间(∆t)呈中度正相关(r=0.37,p=0.008)。
- 校正个体间∆t、肝脏灌注和既往经动脉化疗栓塞差异后,∆t是平均表面偏差的独立预测因子(ß=0.03 mm/min,p=0.01)。
- 与历史对照组相比,仿真使操作时间增加3.5±1.9 min。
诊断标准与关键数值
- 仿真消融区与术后1个月增强CT分割消融区比较:体积相关系数ρ=0.59(p<0.0001),Wilcoxon偏倚检验Z=0.68(p=0.25)。
- 仿真消融区与分割消融区的平均表面偏差(绝对平均误差)为3.4±1.7 mm,Dice相似系数0.62±0.14,敏感度0.70±0.21,阳性预测值0.66±0。
临床应用与阅片要点
- 术前多期CT(含肝脏灌注采集)生成3D肝脏模型,术中CT确定探针位置并半自动配准,可用于患者个体化预估射频消融区以辅助规划肿瘤安全边界。
- 仿真与随访分割消融区体积显著相关且无显著偏倚,但平均表面偏差为3.4±1.7 mm,阅片和报告时需注意仿真消融区与实际消融区之间存在一定几何差异。
- 消融持续时间(∆t)是平均表面偏差的独立预测因子(ß=0.03 mm/min,p=0.01),消融时间越长仿真偏差可能越大。
- 仿真工具使操作时间较历史对照组增加3.5±1.9 min,临床整合时需考虑额外操作时间。
- 作者认为该工具速度和准确性可接受,并建议开展随机对照临床试验评估其潜在的患者结局获益。
局限性
- 作者指出需要进一步随机对照试验评估该工具可能在多大程度上改善患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the accuracy and clinical integrability of a comprehensive simulation tool to plan and predict radiofrequency ablation (RFA) zones in liver tumors.
METHODS: Forty-five patients with 51 malignant hepatic lesions of different origins were included in a prospective multicenter trial. Prior to CT-guided RFA, all patients underwent multiphase CT which included acquisitions for the assessment of liver perfusion. These data were used to generate a 3D model of the liver. The intra-procedural position of the RFA probe was determined by CT and semi-automatically registered to the 3D model. Size and shape of the simulated ablation zones were compared with those of the thermal ablation zones segmented in contrast-enhanced CT images 1 month after RFA; procedure time was compared with a historical control group.
RESULTS: Simulated and segmented ablation zone volumes showed a significant correlation (ρ = 0.59, p < 0.0001) and no significant bias (Wilcoxon's Z = 0.68, p = 0.25). Representative measures of ablation zone comparison were as follows: average surface deviation (absolute average error, AAE) with 3.4 ± 1.7 mm, Dice similarity coefficient 0.62 ± 0.14, sensitivity 0.70 ± 0.21, and positive predictive value 0.66 ± 0. There was a moderate positive correlation between AAE and duration of the ablation (∆t; r = 0.37, p = 0.008). After adjustments for inter-individual differences in ∆t, liver perfusion, and prior transarterial chemoembolization procedures, ∆t was an independent predictor of AAE (ß = 0.03 mm/min, p = 0.01). Compared with a historical control group, the simulation added 3.5 ± 1.9 min to the procedure.
CONCLUSION: The validated simulation tool showed acceptable speed and accuracy in predicting the size and shape of hepatic RFA ablation zones. Further randomized controlled trials are needed to evaluate to what extent this tool might improve patient outcomes.
KEY POINTS: • More reliable, patient-specific intra-procedural estimation of the induced RFA ablation zones in the liver may lead to better planning of the safety margins around tumors. • Dedicated real-time simulation software to predict RFA-induced ablation zones in patients with liver malignancies has shown acceptable agreement with the follow-up results in a first prospective multicenter trial suggesting a randomized controlled clinical trial to evaluate potential outcome benefit for patients.
引用
- Moche M, Busse H, Futterer JJ, et al. Clinical evaluation of in silico planning and real-time simulation of hepatic radiofrequency ablation (ClinicIMPPACT Trial). Eur Radiol. 2019. PMID: 31471752. doi:10.1007/s00330-019-06411-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。